Completed PHASE4 INTERVENTIONAL 3-arm NCT00703313

Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

Sponsor: Santen Inc.

Conditions Healthy

Interventions 0.3% gatifloxacin ophthalmic solution 0.5% moxifloxacin hydrochloride ophthalmic solution 1.5% levofloxacin ophthalmic solution

Updated 5 times since 2017 Last updated: Feb 4, 2009 Started: May 31, 2008 Primary completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00703313, this PHASE4 trial focuses on Healthy and remains completed. Sponsored by Santen Inc., it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Santen Inc.

Data source: Santen Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jacksonville, United States